Publications by authors named "C Tomuleasa"
Myelofibrosis (MF) is a myeloproliferative neoplasm that was most commonly treated with hydroxyurea (HU) prior to approval of ruxolitinib (RUX), now the standard of care. Factors that influence changes in MF treatment in real-world settings are not well understood. The METER study (NCT05444972) was a multi-country retrospective chart review of MF treatment patterns, treatment effectiveness, and healthcare resource utilization.
View Article and Find Full Text PDFChemo- and immune therapies administered to treat haematologic malignancies frequently cause neurologic injury. The adverse events range from mild cognitive impairment and headaches to severe conditions such as seizures, stroke and encephalitis. We performed a comprehensive literature review and report the types, mechanisms, management and prevention of neuro-toxicity resulting from these therapies in subjects who develop these toxic effects.
View Article and Find Full Text PDFReceptor tyrosine kinases (RTKs) are key cell surface receptors involved in cell communication and signal transduction, with great importance in cell growth, differentiation, survival, and metabolism. Dysregulation of RTKs, such as EGFR, VEGFR, HER2 or ROR, could lead to various diseases, particularly cancers. ROR1 has emerged as a promising target in hematological malignancies.
View Article and Find Full Text PDFArticle Synopsis
- Castleman disease (CD) is a rare non-cancerous condition that can be unicentric or multicentric (MCD), with MCD leading to serious symptoms due to cytokine issues, particularly involving interleukin-6 (IL-6).
- This study examined the real-world effectiveness of siltuximab, an anti-IL-6 therapy recommended for idiopathic MCD, in treating patients in Greece and Romania from 2017 to 2022.
- Out of 48 patients treated, 71.1% had a response to the treatment, with a 3-year survival rate of 74%, but some patients experienced adverse effects like elevated liver enzymes and anxiety.